Literature DB >> 9786353

The frequency and clinical significance of neuroendocrine cells within stage III adenocarcinomas of the colon.

E F Foley1, M J Gaffey, H F Frierson.   

Abstract

BACKGROUND: Although colon carcinomas consisting predominantly of neuroendocrine cells carry a worse prognosis than "routine" colon adenocarcinomas, the clinical significance of scattered neoplastic neuroendocrine cells within a typical colon adenocarcinoma remains controversial. The aim of this study was to document the frequency and clinical significance of neuroendocrine cell expression within a stage-specific group of typical adenocarcinomas of the colon.
METHODS: Forty-eight patients with resected stage III adenocarcinomas of the colon were selected from our institutional tumor registry. The pathologic specimens from these patients were reviewed and underwent immunohistochemical staining for chromogranin, a sensitive and specific marker of neuroendocrine differentiation. Long-term (> or = 5 years) clinical outcome was compared with the presence of neuroendocrine cell expression.
RESULTS: Twenty tumors (41.7%) stained positively for chromogranin. Twenty-two patients (45.8%) had long-term cancer-free survival, although chromogranin positivity did not correlate with this survival.
CONCLUSION: The frequency of scattered neuroendocrine cells within colonic adenocarcinomas is high. This finding does not, however, carry the same adverse prognostic implications for cancer survival as does the presence of true neuroendocrine carcinoma of the colon.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9786353

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  10 in total

1.  Rapid four-month growth of an early-stage adenocarcinoma of the colon with neuroendocrine characteristics.

Authors:  Shigetoshi Hosaka; Kenji Matsuzawa; Kazutoshi Maruyama; Hiroyoshi Ota; Taui Akamatsu; Kendo Kiyosawa
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

Review 2.  Neuroendocrine differentiation: The mysterious fellow of colorectal cancer.

Authors:  Britta Kleist; Micaela Poetsch
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

Review 3.  Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?

Authors:  Andrew M Bellizzi
Journal:  Hum Pathol       Date:  2019-12-17       Impact factor: 3.466

Review 4.  The grey zone between pure (neuro)endocrine and non-(neuro)endocrine tumours: a comment on concepts and classification of mixed exocrine-endocrine neoplasms.

Authors:  Marco Volante; Guido Rindi; Mauro Papotti
Journal:  Virchows Arch       Date:  2006-10-11       Impact factor: 4.064

5.  Chromogranin A and chromogranin B in noninvasive and invasive breast carcinoma.

Authors:  Noriko Kimura; Ryuichi Yoshida; Shin-ichiro Shiraishi; Monika Pilichowska; Noriaki Ohuchi
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

Review 6.  Prognostic significance of neuroendocrine differentiation in colorectal adenocarcinoma after radical operation: a meta-analysis.

Authors:  Yu-Jie Zeng; Wei Lai; Lu Liu; Heng Wu; Xing-Xi Luo; Jie Wang; Zhong-Hua Chu
Journal:  J Gastrointest Surg       Date:  2014-02-19       Impact factor: 3.452

7.  Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis.

Authors:  Patricia Grabowski; Isrid Sturm; Katharina Schelwies; Kerstin Maaser; Heinz-Johannes Buhr; Bernd Dörken; Martin Zeitz; Peter T Daniel; Hans Scherübl
Journal:  Int J Colorectal Dis       Date:  2005-06-14       Impact factor: 2.571

Review 8.  Goblet cell carcinoids and other mixed neuroendocrine/nonneuroendocrine neoplasms.

Authors:  Marco Volante; Luisella Righi; Sofia Asioli; Gianni Bussolati; Mauro Papotti
Journal:  Virchows Arch       Date:  2007-08-08       Impact factor: 4.064

9.  Neuroendocrine differentiation is predictive of poor survival in patients with stage II colorectal cancer.

Authors:  Yue Liu; Jinjie He; Jinghong Xu; Jun Li; Yurong Jiao; Dikai Bei; Yeting Hu; Haiyan Chen; Qian Xiao; Kefeng Ding
Journal:  Oncol Lett       Date:  2017-02-07       Impact factor: 2.967

10.  Neuroendocrine differentiation is a prognostic factor for stage II poorly differentiated colorectal cancer.

Authors:  Yue Liu; Jinghong Xu; Yurong Jiao; Yeting Hu; Chenghao Yi; Qiong Li; Zhou Tong; Xiaowei Wang; Lifeng Hu; Qian Xiao; Jun Li; Kefeng Ding
Journal:  Biomed Res Int       Date:  2014-06-29       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.